Ongoing Patent Cliff to Drive the US Generics Market!
According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", The large number of drugs going off-patent in the US presents opportunities for domestic as well as foreign generic drug makers to introduce Generic equivalents of branded products. Some of the players competing in the market include Sun Pharmaceutical Industries Ltd, Teva, Mylan, Actavis, Lupin, Dr Reddy's Laboratories Ltd, Cipla Ltd, Novartis, Roche and Daiichi Sankyo. Patent expirations are estimated to affect more than US$...
View full press release